Success Metrics

Clinical Success Rate
100.0%

Based on 33 completed trials

Completion Rate
100%(33/33)
Active Trials
0(0%)
Results Posted
88%(29 trials)

Phase Distribution

Ph phase_1
2
6%
Ph phase_4
4
12%
Ph phase_3
21
62%
Ph phase_2
7
21%

Phase Distribution

2

Early Stage

7

Mid Stage

25

Late Stage

Phase Distribution34 total trials
Phase 1Safety & dosage
2(5.9%)
Phase 2Efficacy & side effects
7(20.6%)
Phase 3Large-scale testing
21(61.8%)
Phase 4Post-market surveillance
4(11.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

33 of 33 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

34

all time

Status Distribution
Completed(33)
Other(1)

Detailed Status

Completed33
unknown1

Development Timeline

Analytics

Development Status

Total Trials
34
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (5.9%)
Phase 27 (20.6%)
Phase 321 (61.8%)
Phase 44 (11.8%)

Trials by Status

unknown13%
completed3397%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT05028582Phase 3

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

Completed
NCT04973228Phase 3

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Completed
NCT04091646Phase 2

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Completed
NCT01555463Phase 3

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

Completed
NCT02094716Phase 2

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

Completed
NCT04128007Phase 2

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Completed
NCT02815280Phase 3

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Completed
NCT02815267Phase 3

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Completed
NCT03271021Phase 3

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

Completed
NCT04104685Phase 2

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

Completed
NCT03142451Phase 3

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Completed
NCT03506477Phase 4

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

Completed
NCT04608500Phase 3

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Completed
NCT04571151Phase 4

Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis

Unknown
NCT02267746Phase 3

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

Completed
NCT02654769Phase 3

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

Completed
NCT00617903Phase 2

Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea

Completed
NCT01025635Phase 2

Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Completed
NCT03200912Phase 3

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

Completed
NCT03287791Phase 3

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

Completed

Drug Details

Intervention Type
DRUG
Total Trials
34